Oncolytics Biotech Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Oncolytics Biotech Inc., a foreign private issuer, on August 3, 2018. The filing serves to incorporate by reference the company's Management's Discussion and Analysis (MD&A) and Interim Financial Statements for the three and six months ended June 30, 2018. The company is headquartered in Calgary, Alberta, Canada.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific financial data. Revenue, profit, cash flow, margins, debt, and liquidity figures are located in the attached exhibits (Exhibit 99.1 and Exhibit 99.2) which are incorporated by reference but not detailed in this document text.
Material Changes
No material changes or comparative financial data are disclosed within the text of this Form 6-K. Such information is contained within the incorporated MD&A and financial statements.
Guidance, Outlook, and Risks
This filing does not provide specific guidance, outlook, management commentary, or risk factors. These disclosures are found in the incorporated Management's Discussion and Analysis (Exhibit 99.2).
Investor Verification Checklist
- Review Exhibit 99.1 for the full Interim Financial Statements to verify revenue, net loss, and cash position.
- Examine Exhibit 99.2 for management's discussion of operational progress and financial condition.
- Confirm the status of the Registration Statement on Form F-10 (File No. 333-224432) into which this report is incorporated.
- Verify the certifications provided by the CEO and CFO in Exhibits 99.3 and 99.4.